Resource Summary Report

Generated by NIF on Aug 28, 2026

Hepa 1-6

RRID:CVCL_0327
Type: Cell Line

Proper Citation

RCB Cat# RCB1638, RRID:CVCL_0327

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0327

Proper Citation: RCB Cat# RCB1638, RRID:CVCL_0327

Description: Cell line Hepa 1-6 is a Cancer cell line with a species of origin Mus musculus (Mouse)

Sex: Female

Disease: Hepatocellular carcinoma of the mouse

Defining Citation: PMID:11004682, PMID:12606785, PMID:25193168, PMID:26280412, PMID:28152020, PMID:31220119

Comments: Characteristics: Secretes several liver products including albumin, alpha-fetoprotein, alpha 1-antitrypin and amylase (ECACC=92110305).

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: Hepa 1-6

Synonyms: HEPA 1-6, Hepa-1-6, Hepa1-6

Cross References: BTO:BTO_0002895, CLO:CLO_0003711, CLO:CLO_0050769, EFO:EFO_0022833, MCCL:MCC:0000223, CLDB:cl1658, CLDB:cl1659, CLDB:cl5199, AddexBio:C0015005/4999, ATCC:CRL-1830, BCRC:60051, BioSample:SAMN11397636, CCRID:1101MOU-PUMC000106, CCRID:3101MOUSCSP512, CCRID:3101MOUTCM39, CCRID:4201MOU-CCTCC00313, CCRID:6101MOU-CERC000105, CCTCC:GDC0313, CLS:400474, DSMZ:ACC-175, DSMZCellDive:ACC-175, ECACC:92110305, GEO:GSM1374085, GEO:GSM1374086, GEO:GSM1374087, GEO:GSM1374088, GEO:GSM1374089, GEO:GSM1374090, IZSLER:BS TCL 157, Lonza:830, NCBI_Iran:C517, PRIDE:PXD000666, PRIDE:PXD001792, RCB:RCB1638, Ubigene:YC-

A005, Wikidata:Q54882820

ID: CVCL_0327

Vendor: RCB

Catalog Number: RCB1638

Hierarchy: cvcl_s550

Record Creation Time: 20220427T220334+0000

Record Last Update: 20260815T233735+0000

Ratings and Alerts

No rating or validation information has been found for Hepa 1-6.

No alerts have been found for Hepa 1-6.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 792 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Yu S, et al. (2026) Hepatic Stellate Cell-Specific METTL3 Deficiency Promotes Hepatocellular Carcinoma Progression via BMP10-SMAD1/5/8 Signaling. Cancer research communications, 6(5), 1109.

Kong L, et al. (2026) Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Antitumor Immune Evasion. Cancer research, 86(6), 1480.

Zeng Q, et al. (2026) Intratumoral Tertiary Lymphoid Structures Characterized by a B Cell-Related Signature Elicit Antitumor Effect through HAPLN3 in Hepatocellular Carcinoma. Cancer immunology research, 14(5), 771.

Guo Z, et al. (2026) RASGEF1B suppresses hepatocellular carcinoma through the ALDH7A1/Betaine/SNAI1 metabolic?epigenetic axis. Journal of translational medicine, 24(1).

Li Y, et al. (2026) Tumor-Intrinsic ARHGEF3 Enhances Antitumor Immunity by Promoting T-Cell Infiltration and Limiting Myeloid Cell-Mediated Immunosuppression. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(38), e23895.

Liu Y, et al. (2026) Hepatitis B virus promotes hepatocellular carcinogenesis by activating IL-6-dependent tumor-macrophage crosstalk and M2-like macrophage polarization. The

Journal of biological chemistry, 302(8), 113283.

Bi B, et al. (2026) MCT8 Modulates Metabolite Uptake and T-cell Exhaustion to Promote Immunosuppression and Tumor Progression in Hepatocellular Carcinoma. Molecular cancer therapeutics, 25(5), 771.

Liu Z, et al. (2026) AARS1-mediated AKR1B10 lactylation stabilizes an aerobic glycolysis-positive feedback loop to drive lenvatinib resistance in hepatocellular carcinoma. Clinical and translational medicine, 16(1), e70561.

Jiang X, et al. (2026) Targeting Circulating FABP4 Ameliorates Obesity-Associated Hepatic Steatosis. bioRxiv : the preprint server for biology.

Weerasopon K, et al. (2026) Loss of Ezh2 promotes M2-like macrophage polarization in hepatocellular carcinoma. iScience, 29(4), 115180.

Li L, et al. (2026) Tumor-specific glyco-detonators: A neuraminidase-3-gated programmable DNA Nanoarchitectonics for liver cancer-exclusive chemotherapy. Journal of controlled release : official journal of the Controlled Release Society, 390, 114495.

Jia X, et al. (2026) NAD+ hydrolysis catalyzed by SelO is required for mitochondrial homeostasis. Cell, 189(9), 2633.

Qu C, et al. (2026) Targeted extracellular vesicle-photoimmunotherapy remodels stromal-immune microenvironment to boost chemo-immunotherapy in preclinical models. Cell reports. Medicine, 7(7), 102843.

Su LP, et al. (2026) Dual Specificity Phosphatase 4 Enhances Immunotherapy Response by Inhibiting TGF-?1 Secretion in Hepatocellular Carcinoma. Cancers, 18(8).

Gu Y, et al. (2026) Sunitinib induces immunogenic cell death through eIF2? phosphorylation to potentiate immunotherapy in HCC. iScience, 29(4), 115378.

Hao X, et al. (2026) Engineered CAR-NKT Extracellular Vesicles Suppress Tumor Progression and Enhance Antitumor Immunity. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(13), e21623.

Wang M, et al. (2026) Elemene Augments the Effects of Anti-PD-1 Immunotherapy on Hepatocellular Carcinoma by Regulating the miR-130a-5p/SPP/MHC-I Axis. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(11), e11887.

Yan L, et al. (2026) The Erlin1/2 complex is a dynamic scaffold for membrane microdomain assembly on the endoplasmic reticulum. Molecular cell, 86(7), 1362.

Zhao Y, et al. (2026) Physiological respiration pressure-driven piezocatalytic therapy for malignant ascites with a gold-core magnified mesoporous piezoelectric nanoplatform. Biomaterials, 333, 124233.

Khanduja S, et al. (2026) Salmonella vector creates de novo parvovirus that reduces solid tumors and forms antitumor immune memory. Cell reports. Medicine, 7(6), 102839.